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Lentiviral vectors are useful experimental tools for stable gene delivery and have been used to treat human
inherited genetic disorders and hematologic malignancies with promising results. Because some of the
lentiviralvectorcomponentsarecytotoxic,transientplasmidtransfectionhasbeenusedtoproducethelarge
batches needed for clinical trials. However, this method is costly, poorly reproducible and hard to scale up.
Herewedescribeageneralmethodforconstructionofstablepackagingcelllinesthatcontinuouslyproduce
lentiviralvectors.ThisusesCrerecombinase-mediatedcassetteexchangetoinsertacodon-optimisedHIV-1
Gag-Pol expression construct in a continuously expressed locus in 293FT cells. Subsequently Rev, envelope
and vector genome expression cassettes are serially transfected. Vector titers in excess of 10
6 transducing
units/ml can be harvested from the final producer clones, which can be increased to 10
8 TU/ml by
concentration. This method will be of use to all basic and clinical investigators who wish to produce large
batches of lentiviral vectors.
L
entiviral vectors(LV) have been usedbymanyinvestigators to modify cells invitro andin vivo,because they
can integrate a transgene or shRNA into the genome of most cell types
1. This work has extended to clinical
trials using LV to modify bone marrow stem cells from patients with inherited genetic disorders; subsequent
transplantation of the modified cells has resulted in clinical benefit for several severe conditions
2,3. LV-modified
autologous T cells have also been used in clinical trials to treat malignancies yielding encouraging results
4.
As LV are replication defective, they need to be produced by co-expression of their constituents in one
producercell.Theseconstituentsareusuallyprovidedinthreeorfourseparateplasmids.TheGag-Polexpression
cassette encodes HIV structural proteins and enzymes. Another cassette encodes Rev, which is an HIV accessory
protein necessary for vector genome nuclear export. A third cassette encodes a heterologous envelope protein,
often thatof theGprotein fromvesicularstomatitis virus (VSV-G), thatallows LVparticleentry into targetcells.
Another cassette encodes the vector genome itself, which carries signals for incorporation into particles and an
internal promoter driving transgene expression. The construction of stable packaging cell lines expressing all
thesecomponentsathighlevelshasbeenchallenging.Notably,theHIVGag-Polcassettehasprovedimpossibleto
expresscontinuouslyathighlevelbyplasmidtransfectionfollowedbyantibioticselectionforplasmidintegration.
The cytotoxicity of Gag-Pol proteins has been suggested as a possible cause for this problem
5,6. The commonly
usedVSV-Genvelopeisalsocytotoxic
7.Therefore,mostLVbatches,includingthoseusedinclinicaltrialstodate,
have been produced by transient transfection of HEK293T cells with multiple plasmids
8–14. Such transfection is
expensive,hardtoreproduceatlargescale,andresultsincontaminationoftheLVpreparationwithplasmidsand
cellular debris
15.
LVproductionbystableproducercelllines(PCLs)wouldavoidsomeoftheseproblemsandwillbeparticularly
necessary to produce batches of LV for larger clinical trials and future gene medicines. As an alternative to
continuous, constitutive vector production, inducible PCLs have been developed wherein inducible cassettes are
used to express packaging functions. Only one of the reported inducible HIV-based PCLs, named GPRG, has
been proposed for the production of therapeutic vectors for use in clinical trials targeting SCID-Xl
16,17. Another
inducible EIAV-based LV producer cell line has been developed to make therapeutic vectors for use in clinical
trials targeting Parkinson’s disease
18,19. However, the scaling-up of inducible systems necessary for clinical-grade
LV production is problematic, and additional purification steps of the vector preps to eliminate inducing agents
OPEN
SUBJECT AREAS:
BIOTECHNOLOGY
GENE THERAPY
Received
8 October 2014
Accepted
9 February 2015
Published
12 March 2015
Correspondence and
requests for materials
should be addressed to
Y.T. (y.takeuchi@ucl.
ac.uk)
*These authors
contributed equally to
this work.
{These authors jointly
supervised this work.
SCIENTIFIC REPORTS | 5 : 9021 | DOI: 10.1038/srep09021 1are required. Furthermore, vector production rapidly declines as a
result of instability of producer cell clones following induction
20–22.
We previously constructed continuous, high-titer LV packaging
cellscalled STAR
23.ToavoidtheproblemofVSV-G toxicityweused
an envelope derived from the gammaretrovirus RD114, with the R-
peptide cleavage site replaced with that of HIV-1 protease
23. This
mediatesparticularly efficient transduction of human hematopoietic
stem cells (HSCs) and T cells
24–26, which are important clinical gene
therapy targets. We used gammaretroviral vectors (GRV) to express
a codon-optimized HIV-1 Gag-Pol and Rev in STAR cells. This
resulted in insertion of HIV-1 Gag-Pol in chromosomal loci that
allowed its high-level, stable expression
23. However, Gag-Pol and
Rev expression could be lost in these cells as they were not main-
tained under antibiotic selection. There was also a possibility of
packaging a GRV encoding Gag-Pol and Rev within LV particles
making the vectors unsuitable for clinical application. Another con-
stitutive PCL reported recently, RD2-MolPack
27, used SIN LV to
introduce HIV-1 tat and an RD114-derived envelope, which may
pose safety concerns as these LVs might be packaged. It also has
Gag-Pol and Rev in a single construct, which is another safety con-
cernasitreducesthenumberofrecombinationsrequiredtogenerate
wild-typeHIV.Furthermore,themethodreportedtointroducenon-
SIN LV into RD2-MolPack by transduction is not applicable to SIN
LV, which are required for most gene therapy applications.
Here, we report a method that solves all these problems for gen-
erationofstableLVpackagingandproducercelllinesexemplifiedby
the construction of WinPac cells. These cells are uniquely capable of
producing self-inactivating (SIN) LVs at relatively high titers for
prolonged periods.
Results
Constitutive HIV-1 Gag-Pol expression via recombinase
mediated cassette exchange (RMCE). Traceability of clinical
vector producer cell lines is likely to be required in the current
good manufacturing practice (cGMP) regulation. Traceable 293FT
cells with well-documented culture history
28 were therefore used for
packaging cell development. We designed a strategy to introduce a
codon-optimized HIV-1 Gag-Pol by recombinase mediated cassette
exchange
29,30. This strategy takes advantage of GRV‘s ability to
integrate within chromosomal loci that can support constitutive,
high-level expression of HIV-1 Gag-Pol but minimizes GRV
derived sequences remaining in the final packaging cells
(Figure 1a). An MLV-based GRV encoding a Hygro-eGFP hybrid
with an LE mutant LoxP site cloned into its 39 U3 region, pSLS51
(Supplementary Figure S4a), was used to transduce 293FT cells at
low MOI and the cells were then selected in hygromycin (Figure 1a
Before RMCE). Among the hygromycin resistant clones we selected
clone 2 g, which had a single vector copy per cell as determined by
Figure 1 | StableexpressionofHIV-1Gag-Polin293FTcellsviaCrerecombinase-mediatedcassetteexchange(RMCE).(a)Schematicrepresentationof
RMCE to introduce codon-optimized HIV-1 Gag-Pol at a transcriptionally active chromosomal locus. Neo, Neomycin resistance gene; CMV,
Cytomegalovirus promoter; Hygro-eGFP, hygromycin-resistance gene and eGFP fusion transgene; Puro, puromycin resistance gene. (b) GFP mean
fluorescence intensity (MFI) as determined by FACS analysis of hygromycin-resistant clones following transduction with the lox-P tagging MLV vector.
ThemedianMFIwas195(range78–359).Clone2G(boxed)waschosenforfurtherexperimentsbasedontherelativelyhighMFI,superiorstabilityofMFI
over 50 passages, and a single copy of the tagging vector by Q-PCR (data not shown). (c) Levels of HIV-1 p24 in culture supernatant of puromycin-
resistant clones following the co-transfection of the Cre recombinase-encoding plasmind (pCAGGS Cre) and pSLS94 containing the HIV-1 Gag-Pol
exchangecassette.Themedianp24was0.095 ng/ml(range0–0.23).GFPMFIasdeterminedbyFACSanalysisofpuromycin-resistantclonesisalsoshown.
Clone 57 was chosen for further experiments based on highest p24 levels and loss of eGFP expression following RMCE reaction.
www.nature.com/scientificreports
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than 50 passages (Figure 1b). The vector integration site was
identified by inverse PCR as nucleotide position 10619185 in the
first intron of midline 1 gene (MID1) on the X chromosome
(GRCh38 assembly, 2013 Dec release), the vector was integrated in
reverse orientation to the MID1 gene.
Subsequently, a plasmid encoding a codon-optimized H87Q
Gag-Pol mutant driven by CMV promoter and flanked by RE
mutant LoxP sites was constructed, pSLS94 (Supplementary
Figure S4a). The H87Q mutant is a naturally occurring capsid
mutation that enhances transduction of mouse and monkey cells
without compromising transduction of human cells
31–33.T h i sc a n
facilitate pre-clinical testing using these vectors. Additionally, there
was a more extensive optimization in this current construct accord-
ing to codon optimization indices, compared to our previous HIV-
1 Gag-Pol construct used in STAR cells (Supplementary Table S1).
A promoter-less puromycin resistance gene with a polyA signal was
also cloned downstream from the 59 RE mutant LoxP site. This
plasmid (pSLS94) was co-transfected with a Cre-recombinase-
encoding plasmid resulting in recombination between the inte-
grated LE mutant LoxP sites and the RE mutant LoxP sites in
pSLS94 (Figure 1a After RMCE). As a result, the Gag-Pol express-
ion cassette was integrated between a double (LE 1 RE) mutant
LoxP site and a wild type LoxP site. Since Cre-recombinase has low
affinity to the former, the cassette will remain stably integrated
29.
Puromycin-resistant clones were then tested for successful Cre-
mediated recombination by the absence of GFP expression (by flow
cytometry) and HIV-1 Gag-Pol expression levels (by HIV-1 p24
ELISA). Clone 57 was chosen for further experiments as it had
high level Gag-Pol expression and had lost GFP expression
(Figure 1c).
Establishment of a WinPac-RD packaging cell line: introduction
of HIV-1 Rev and an RDpro envelope. The remaining vector
components were introduced by a series of plasmid DNA transfec-
tion, antibiotic selection, cell cloning and clone screening (Figure 2a).
Firstly, HIV-1 Rev, which is required for nuclear export of vector
genomes containing Rev response element (RRE), and secondly,
RDpro envelope, derived form the gammaretroviral RD114
envelope glycoprotein
23, were introduced. Cell clones at each step
were screened for both RNA expression and vector production by
transient transfection of missing vector components. The best
performing clones, WinPac and WinPac-RD respectively, were
selected for further study (described in detail in the supplementary
information, Cell Construction and Figures S5 and S6). For
comparison we included STAR cells with RDpro envelope (STAR-
RDpro) as well as an alternative cell construct, Clone F (Figure 2b), in
transient vector production assays (Figure 2c). Clone F was based on
293FT cells, like WinPac cells, and contains an HIV-1 Gag-Pol
expression cassette introduced by a self-inactivating GRV
proviruses to minimize the risk of Gag-Pol RNA packaging.
WinPac-RD cells achieved a similar titer as the standard three
plasmid transfection of 293FT cells with HIV-1 Gag-Pol, Rev,
RDpro and vector, and to transient transfection of STAR-RDpro
cells with vector alone. Clone F was least effective and not used for
further development (Figure 2c).
Figure 2 | Establishment of (pre-)packaging cell line with a RD114-derived envelope. (a) Construction steps of WinPac-RD (pre-)packaging cell line.
(b)Constructionstepsofanalternative(pre-)packagingcelllineusingself-inactivatingMLVvectorforGag-Polexpression,CloneF(c)Trialsoftransient
vector production. Transient transfection of SIN GFP-encoding HIV-1 vector plasmid in (pre-) packaging cell lines were compared with 3 plasmid
transfection of parental 293FT cells. Data shown represents mean 1/2 SD from 8 independent experiments.
www.nature.com/scientificreports
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cells constitutively expressed all packaging functions, Gag-Pol, Rev
and envelope, to package HIV-1 vector genomes. The final step to
establish continuous LV producer cells was to express vector
genomic RNA. SIN LVs contain a deletion within the LTR U3
region. This deletion makes them less genotoxic
34–36 and more
likely to be widely used for clinical applications. Therefore, we
transfected a GFP-expressing SIN LV, SIN-pHV (Supplementary
Figure S4b), into WinPac-RD cells. We aimed to produce culture
supernatants with LV transduction titers of at least 10
5 transduction
units (TU)/ml, as the final product for clinical use after vector
concentration and purification may be required to be of more than
10
7 TU/ml.
Before transfectionof theSINLV, WinPac-RDcells werecultured
in the presence of puromycin, hygromycin and phleomycin for 9
days to ensure the majority of cells express all the packaging func-
tions that are genetically linked to respective antibiotic resistance
genes. Subsequently, SIN pHV was co-transfected with pSELECT
BlastiMCS(encodingtheblasticidinresistancegene-Bsr)atamolar
ratio of 1051. Twenty two cell clones (WinPac-RD-HV shortened to
WRH) were obtained from a blasticidin-resistant bulk population of
cells which produced SIN-pHV at titers of .10
4 293T TU/ml
(Figure3a).Oneoftheseclones(WRH26)producedLVtitershigher
than 1 3 10
5 TU/ml (Figure 3b, blasticidin selected). Because the
stable transfection of a new vector component may be associated
with a reduction in expression of pre-existing packaging functions,
the clones were also re-selected with puromycin and hygromycin to
ensure that the packaging components were expressed at relatively
high levels. Three more clones (WRH1, WRH2, and WRH29)
with titers of <1 3 10
5 TU/ml were identified (Figure 3b, BPuH
selected).
To confirm that re-selection with antibiotics can reproducibly
increase LV titers, unselected WRH clones were thawed out and
re-selected in a stepwise manner with the four antibiotics (blastici-
din, puromycin, hygromycin, and phleomycin). Functional titres
were determined after the addition of each of the antibiotics
(Figure 3c). Importantly, selection of WRH clones with antibiotics
raised titers to <10
5 293T TU/ml. Moreover, these titers were stable
for $4 weeks of culture following removal of antibiotics (Figure 3c).
To further demonstrate the stability of WinPac-derived producer
cells, clone WRH1 was kept in culture with or without antibiotics
andtransductiontitersweredeterminedat2–4weekintervals.Titers
wererelativelystableoveraperiodofaround4monthsintheabsence
of antibiotics, and for around 5 monthsin the presence of antibiotics
(Figure 3d). It should be noted that the all titers shown in Figure 3
represent sub-optimal values as vectors were harvested from small
numbers of cells in order to screen multiple clones and to test a
number of antibiotic selection procedures.
Figure 3 | Establishment of stable producers for a GFP-coding SIN-HIV vector. (a) Screening steps for high-titer vector producer cell lines. (b)
Screening ofblasticidin-resistant clones stably co-transfected with SIN pHV and pSELECT Blasti MCSbefore and after re-selection with puromycin and
hygromycin in the presence of blasticidin (BPuH). Clones WinPac-RD-HV (WRH) 1, 2, 26, and 29 were chosen for further experiments (boxed). Black
horizontalline:thresholdlevelofdetection.Downwardarrows:titersbelowthreshold.Datashownrepresentsmeanoftworeplicates.Themediantiterof
all screened BPuH-resistant clones was 1.66 3 10
4 293T TU/ml (range: 3.05 3 10
3–1.25 3 10
5). (c) Titers of the four WRH clones during step-wise drug
re-selection(blasticin1phleomycin1puromycin1hygromycin(BPlPuH)),andafter$4weeksfollowingtheremovalofantibiotics(mean1/2SEof
two replicates). (d) Stability of titers during long-term (.5 months) culture in the presence or absence of antibiotic selection (mean 1/2 SE of two
replicates).
www.nature.com/scientificreports
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then conducted to determine the optimal harvesting conditions for
WRH clones (data not shown). These experiments showed that
higher titers were achieved when cells were fully confluent at the
start of a 24-hour vector production period. Optimal harvests were
collected beginning at 72 hours after seeding under following
conditions: seeding density 5 2.1–2.3 3 10
5 cells/cm
2 and harvest
volume(ml):surfacearea(cm
2)ratio<0.1.Optimizedharvestsfrom
the producer clones had average titers up to 3 3 10
6 293T TU/ml
(Figure 4a, -spinoculation). It has been previously shown that
spinoculation improves the efficiency of transduction of HIV-1-
based vectors by depositing the vectors onto the target cells
37.
Accordingly, spinoculation resulted in 2–3 fold increase in titers
(up to 5 3 10
6 TU/ml) (Figure 4a, 1spinoculation). Vector
production was also scaled up to allow the collection of 640 ml or
560 ml per harvest using 10-layer CellSTACKs (Corning) or
HYPERFlasks (Corning) respectively. After scale up, vector titers
had a mean of 7.28 3 10
6 (SD 5 1.47 3 10
6) and 5.00 3 10
6 (SD
5 8.02 3 10
5) 293T TU/ml over four days, respectively (Figure 4b).
The mean productivity per cell was 1.75 (SD 5 0.28) TU/cell/day.
Additionally, cells tolerated reduction of FCS concentration down to
1%inHYPERFlaskandcontinuedtoproduce.5310
6 TU/mlupto
the 6
th harvest (Figure 4B and data not shown). Such reduction of
serum in vector harvests would help downstream vector processing.
HIV-1 p24 level and transduction titers were compared for vector
harvests from stable WinPac- and STAR-derived vector producer
cells as well as transient 293FT producers for RDpro and VSV pseu-
dotyped vectors (Figure 4c). HIV p24 levels and transduction were
not significantly different between RDpro pseudotyped vectors,
regardless of whether they were stably or transiently produced. In
contrast VSV-G pseudotyped vectors had significantly higher trans-
duction rate per physical particle as measured by p24 ELISA
Figure 4 | Optimization of vector production and primary cell transduction. (a) Optimised GFP infectious titers of the four WinPac-RD-HV (WRH)
clones cultured in 6-well plates after re-selection with Blasticidin, Phleomycin, Puromycin, and Hygromycin (BPlPuH). Vectors were titrated on 293T
cells with/without spinoculation (mean 1/2 SD of three independent experiments). (b) Scaled up vector harvests using 10-layer CellSTACK and
HYPERFlask,collecteddailyfrom72 h(H1)to144 h(H4)aftercellseeding,weretitratedforGFPtransduction.Vectorswereharvestedwitheither10%
(D10)or1%(D1)FCS.CellsinHYPERFlaskwith1%FCSlastedtwomore daysandkeptproducing5310
6 TU/mltiters (datanot shown).Datashown
representsmean1/2SEoftworeplicates.(c)GFPinfectioustitersandHIV-1p24concentration(ng/ml)ofvectorharvests.Datashownrepresentsthree
independent harvests from each of the following: WRH1 and WRH2 (WinPac-RD derived producer clones expressing SIN HV vector harvested from
T175 flasks); SRH (STAR-RDpro derived producer cells expressing non-SIN HV vector harvested from T175 flasks), RDpro LV (produced by 3 plasmid
transienttransfectionof293FTcellsin10 cm
2platesusingaRDproenvexpressingplasmid);VSV-GLV(producedby3plasmidtransienttransfectionof
293FT cells in 10 cm
2 plates using a VSV-G expressing plasmid). WRH2 HF D10 and WRH2 HF D1 samples represent multiple harvests obtained from
clone WRH2 cultured in a HYPERFlask and harvested in the presence of 10% or 1% FBS, respectively. WRH2 CS D10 sample was obtained from clone
WRH2 cultured in a 10-layer CellSTACK. (d) T cells from two donors and CD341 cells from one donor were challenged by LV containing the GFP
encoding SIN-HV vectors either stably produced by WinPac-RD-derived cells (WRH) or transiently produced by 293FT cells using VSV-G expressin
plasmid (VSV-G LV) at two different vector doses: multiplicity of infection (MOI) was based on infectious titers on 293T cells. For T cells, data shown
represents mean 1/2 SE from two donors calculated from triplicates.
www.nature.com/scientificreports
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G LVs in comparison to RDpro-pseudotyped LVs on immortalized
cell lines, such as 293T cells, have been previously reported
23,38,39.
However, of note, HYPERFlask harvests of WinPac–RD superna-
tants had about 10-fold higher ratio of 293T transducing units /p24
level compared with small-scale routine harvests (mean ratios of 4.2
3 10
4versus 3.0310
3293TTU/ngp24respectively, Supplementary
Figure S1).
Vector processing including concentration and purification is
required before any clinical application. Because LVs pseudotyped
with c-retroviral envelopes may be mechanically more fragile than
VSV-G pseudotyped vectors, we tested two concentration methods
on our stably produced RDpro enveloped vectors: low-speed cent-
rifugation at 4000 3 g for 18 hr and tangential flow filtration (TFF)
using 500 kDa cut-off hollow fiber (Supplementary Figure S2). The
vector titers reached 7–9 3 10
7 TU/ml in these concentration trials.
CD341 cell and T cells are important targets in human gene
therapy
8–14. We therefore tested the transduction efficiency of our
stably produced RDpro-pseudotyped LVs and compared it to that of
transiently-produced VSV-G-pseudotyped LVs. Equal number of
293TTUwereusedtotransduceeitherhumanbonemarrow-derived
CD341 cells or human T cells by pre-loading retronectin-coated
plates. For both cell types, stably produced RDpro pseudotypes out-
performed VSV-G pseudotypes especially at lower MOIs (Fig. 4d).
Effects of levels of vector components on vector titers. In order to
determine which vector component(s) influence vector production
efficiency, i.e. vector titers, we measured DNA (Figure 5) and RNA
(Figure 6) levels in a number of vector producer clones at two time
points during continuous culture approximately 10 weeks apart
(early and late). Vector titers of corresponding harvests were also
measured at the same two time points. The DNA copy number for
Gag-Pol, at the lox-P tagged locus, was stable in WinPac derived cell
lines (Figure 5a). Consistent with our previous report
23, STAR-
derived cells contained multiple Gag-Pol copies. Notably, the
stable DNA copy numbers of the SIN-HV genome DNA in the
tested clones (Figure 5d) suggest the absence of significant auto-
transduction likely due to the interference phenomenon
40. Gag-Pol
RNA levels were relatively stable suggesting that the lox-P tagged
locus can support high expression levels long-term (Figure 5e).
RDpro env and Rev RNA levels decreased with time in some of the
clones tested.
We then compared vector titers with component RNA levels to
examine which RNA might be limiting for vector titer in a variety of
WRH and SRH clones. Figure 6 shows that RNA levels for Gag-Pol,
Rev and SIN-HV genome, but not that for RDpro env, positively
correlated with transduction titers (Figure 6). This suggests that
particular attention should be paid to expression levels of Gag-Pol,
Rev and vector genome. Examination of individual clones suggested
that any of these could limit vector titer (WRH1 (early, BPlPuH):
vectorgenome, WRH2 (early, no antibiotics): Gag-Pol/Rev, WRH26
(early, no antibiotics): Rev, Figure 6).
Safety characteristics. APOBEC3G (A3G) belongs to the apoli-
poprotein B mRNA editing enzyme catalytic polypeptide-like
(APOBEC) family of proteins and was initially identified as a
potent restriction factor against HIV-1 infection in human CD41
T cells
41. APOBEC3G-mediated G to A hypermutation in integrated
proviral copies of c-retroviral vectors produced by the HT1080-
derived FLYA13 packaging cell lines has been previously
demonstrated
42. These mutations can have important conse-
quences if they occur in the region coding for the therapeutic gene
of interest, as they may lead to decreased levels of production, or the
production of an inactive or immunogenic variant of the therapeutic
protein. However, no hypermutation of vectors produced by 293
cells was detectable
42. This is consistent with a previous report
demonstrating that A3G RNA was undetectable in 293T cells
43.
Thus, we tested whether WinPac cells express A3G or not at
various stages of their development. As expected, APOBEC3G
protein was not detected by western blot in WinPac, WinPac-RD,
and WinPac-RD-HV1 cells (Supplementary Figure S3a).
We hypothesized that stable LV production yields preparations
containing less plasmid DNA and cell-derived contaminants, com-
pared to transient production methods. Importantly, plasmid DNA
contaminants in clinical vector preparations can potentially induce
immuneresponsesviaToll-LikeReceptors
15.Tocomparetherelative
amounts of such contaminants in untreated stably- and transiently-
produced vector preparations, Q-PCR-based assays were used to
detect cell-derived DNA encoding SV40T Ag and plasmid DNA
(Supplementary Figure S3b). Although there were similar levels of
cell-derived DNA in all preparations tested, there were higher levels
of plasmid DNA in transiently produced vector preparations.
Discussion
Here,wehavedemonstratedthatitispossibletoexpressHIV-1Gag-
Polconstitutively, at a high level, from a single copy cassette inserted
into the producer cell genome by Cre-mediated cassette exchange.
We chose to insert the target LoxP sites using a GRV vector as we
previously demonstrated that GRV insertion sites would support
HIV-1 Gag-Pol expression. This method could be adapted to use
CRISPR-Cas technology to insert LoxP sites into known loci. It will
also be possible to modify the Gag-Pol expression cassette to test
other enhancer/promoters. We chose the CMV immediate early
promoter since it worked well in STAR cells. Likewise, the Rev
expression cassette could be modified. However, our experience
shows that both Gag-Pol and Rev should be re-selectable by anti-
biotic resistance, and should be expressed as highly as possible as we
have shown that their expression levels correlate positively with LV
titer.
Furthermore,wehaveshownthatlinkingexpressionofthevarious
vectorcomponentswiththatofselectablemarkersensureshightiters
are achieved. Practically, we would recommend re-selection with
antibiotics before and after the expression of new vector component
in packaging cells as well as after thawing out producer cells.
Subsequently, cell culture can be scaled up and vector batch produc-
tion can be reliably undertaken in the absence of antibiotics.
We chose to stably express the RDpro envelope protein to exem-
plify the method. Other non-cytotoxic viral envelopes could be sub-
stituted, such as those from amphotropic murine leukemia virus or
Gibbon ape leukemia virus, which have been used in clinical gene
therapy trials with GRV
44. It would also be possible to use an indu-
cible construct for a cytotoxic envelope such as VSV-G, in cells con-
taining all the other LV components. This induction in the presence
of optimal expression of Gag-Pol, Rev and SIN vector, should be
moreefficientthansimultaneous inductionofmultiple components.
Our novel, clinical-grade WinPac cells with the RD114-derived
envelope,RDpro,cancontinuouslyproducethirdgenerationSINLV
attitersintheorderof10
6 TU/ml.Incurrentsuccessful,genetherapy
trials, roughly 1–40 3 10
9 infectious units of vectors per patient are
required
8–11.Itiscertainlyfeasibletoproduceclinicallyusefulbatches
of therapeutic LV by optimized scaling-up of cell culture, vector
harvestandprocessing using WinPac-RD packagingcells. Such con-
tinuous LV production methods will have considerable advantages
over current transient vector production methods, being cheaper,
more reproducible and lower in contaminants.
Compared to currently available PCLs, WinPac cells can support
the production of SIN LV at superior titers compared to the other
constitutiveLVPCLreportedtodate
27.IncontrasttoinduciblePCLs
proposed for clinical LV production, like the GPRG cell line
16, con-
tinuous production using WinPac cells is easier to scale up and
avoids the rapid decline in titers following induction. Interestingly,
WinPac-derived producers had titers similar to GPRG-derived
producers obtained following plasmid transfection as opposed to
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 5 : 9021 | DOI: 10.1038/srep09021 6Figure 5 | DNA copy numbers and RNA expression levels of each vector component in packaging and producer cell lines. DNA copy numbers per cell
for Gag-Pol (a) Rev (b), RDpro (c) and Genome (d, primers used amplify the HIV-1 leader sequence) measured by qPCR. Cell number per reaction
was estimated by performing qPCR for b-actin in parallel. Data shown represents mean of two replicates. (e) RNA expression levels per DNA copy
number of each vector component are shown. RNA expression levels were measured by q-RT-PCR and normalized to the b-actin RNA expression levels
in each sample and divided by the corresponding DNA copy number. Early (after <2–4 weeks in culture) and late (after <12–14 weeks in culture) time
points were around 8–10 weeks apart.
www.nature.com/scientificreports
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is less stable.
Notably, the expression level of the SIN vector genome in our
modelproducercellsissuboptimalandlimitstiters.Thehighesttiter
producer cell lines from STAR-RDpro contained a transfer vector
carrying a full length LTR in the presence of HIV-1 tat. This might
account for the higher expression of the vector genome RNA.
Therefore,wearecurrentlyoptimizingtheexpressionlevelforthera-
peutic SIN vector production in WinPac cells using alternative tech-
niques including RMCE at a pre-defined locus. This strategy would
facilitate the reproducible construction of various producer cell lines
fromamasterpackagingcellline.Moreover,wearedevelopingstable
producercelllinesfortherapeuticLVproductionforthetreatmentof
X-linkedSevereCombined Immunodeficiency (SCID-X1)andBcell
malignancies. To facilitate the use of these cell lines, optimization of
thedownstreamprocessingprotocolsforRDpro-pseudotypedLVsis
warranted.
Methods
Cell Culture. HEK293T, HEK293FT (Genethon, Evry, France), HeLa, HT1080,
WinPac, STAR, and FLY cells were cultured in DMEM (Dulbecco’s Modified
Eagle Medium) containing Glutamax (GIBCO, Carslbad, CA), supplemented with
50 U/ml Penicillin, 50 mg/ml Streptomycin (GIBCO) and 10% FBS (Sigma-
Aldrich, St Louis, MO/GIBCO) at 37uC and 5% CO2. When indicated, antibiotics
were added to the culture medium (Antibiotics and their working concentration
are listed in the Supplementary Table S4). The lot numbers of all reagents added
to 293FT cells and all cell lines derived from it potentially for future clinical use
have been documented.
LV production from producer cell lines. Cells were seeded at a density of 2.1–2.3 3
10
5 cell/cm
2.After72 hours,cells werewashedwith mediumand 0.08–0.1 ml/cm
2of
medium was replaced except for HYPERFlasks for which 0.33 ml/cm
2 medium was
used. 24 hours later, vector-containing medium (VCM) was collected, passed
through 0.45 mmfilter and storedat 280uC.Fresh mediumwasaddedtothe cells for
collection after 24 hours. This process was repeated for up to six times.
Transient LV Production. Three-plasmid co-transfection into HEK293FT cells was
used to make pseudotyped LV as described previously
45. Briefly, 6 3 10
6 293FT cells
were seeded in 10 cm
2 plates. 24 hours later, they were transfected using fugene6
(Promega, Madison, WI) with following plasmids: SIN pHV (vector plasmid), p8.91
(Gag-Pol expression plasmid
45,), and either pMD.G (VSV-G env expression
plasmid
46,) or pRDproLF (RD114-derived env expression plasmid
23,). Medium
was changed after 24 hours and then VCM was collected over 24-hour periods for 3
days. Following collection, VCM was passed through 0.45 mm filter and stored at
280uC.
LV Concentration. WinPac-RD-HV, RDpro LV and VSV-G LV preparations were
concentrated bycentrifugationina HeraeusMegafuge (Thermo Scientific, Waltham,
MA) at 4000 3 g for18 hours at 4uC. The pellet was resuspended in ice cold X-
VIVO10 (Lonza) and stored at 280uC. Alternatively, vector preparations were
concentrated by tangential flow filtration (TFF) using a KrosFlo Research IIi System
and a 115 cm
2 500 kDa cut-off PES hollow fibre (Spectrum Labs, Rancho
Dominguez, CA).
LVTitration.Thefunctionaltiterofeachvectorpreparation wasdeterminedbyflow
cytometricanalysisforGFPexpressionfollowingtransductionof293Tcells.Briefly,6
3 105 293T cells were infected with LV plus 8 mg/ml polybrene (Sigma-Aldrich) for
24 hours. Infected cells were detected by eGFP expression using FACSCalibur (BD
Biosciences, San Jose, CA) and Flowjo software at 48 hours following the start of
transduction. Titers were calculated from virus dilutions where 1–20% of the cell
population was EGFP-positive using the following formula:
Figure 6 | Correlation between RNA expression levels of vector components and functional titers. Points in each graph represent the RNA expression
levelsofthevariouscomponentsattheEarlyandLatetimepointsforthefourWinPac-RD-HV(WRH)producerclones(whilegrowinginthepresenceor
absence of selection antibiotics) and STAR-RDpro-HV (SRH) cells plotted against the titers determined at the time of RNA extraction. The data
represents the mean of two replicates. Black: SRH, Orange: WRH1 Early BPlPuH, Red: WRH2 Early no antibiotics, Blue: WRH1 Late no antibiotics,
Green: WRH26 Early no antibiotics, White: remaining WRH.
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Primary cell transduction. For T cell transduction, whole blood was collected from
donors following signed consent under sterile conditions. PBMCs were isolated by
Ficoll (GE Healthcare, Little Chalfont, UK) gradient centrifugation, re-suspended in
X-VIVO 10 (Lonza, Basel, Switzerland), stimulated overnight with 0.5 mg/ml OKT3
(anti-CD3, Miltenyi Biotech, Auburn, CA) and 0.5 mg/ml anti-CD28 (Miltenyi
Biotech). IL-2 (Proleukin, Chiron, Emeryville, CA) was added at a concentration of
100 international units (IU)/ml following overnight stimulation. On the next day, T-
cells were harvested, seeded at 3 3 10
5 cells per well, and spun at 1000 g for 40
minutes at room temperature on 24-well plates previously coated with the CH-296
fragment of fibronectin (Retronectin, Takara, New York, NY) and preloaded with
TFF-concentrated vector supernatant at MOI 1 or 5 (based on 293T transduction
units).After72 hoursincubation,Tcellswereharvestedandre-suspendedinfreshX-
VIVO 10 medium supplemented with 100 TU/ml IL-2. 72 hours later (6 days post-
transduction), transduced T cells were analyzed for GFP expression by flow
cytometry (FACSCalibur, BD Biosciences).
Human CD341 cells were isolated from G-CSF mobilized peripheral blood of a
healthy donor using the Diamond CD34 Isolation Kit (Miltenyi Biotec). Cells were
cultured in X-VIVO 10 plus 1% human serum albumin (HSA), supplemented with
stem cell factor (hSCF) at 100 ng/ml; human Flt3-ligand (hFlt-3L) at 100 ng/ml;
thrombopoietin (hTPO) at 100 ng/ml; and human interleukin 3 (hIL3) at 20 ng/ml
(all from Peprotech, London, UK) for three days before transduction.
For CD341 cell transduction, 24-well plates were coated with Retronectin
(Takara). Concentrated GFP-encoding LVs (WinPac-RD-HV1 or VSV-G LV) were
preloaded (by centrifugation at 1200 g at 32uC for 40 minutes) onto the retronectin-
coated plates and the supernatant was discarded. 1 3 10
5 hCD341 cells were
transduced overnight at MOI 0.5 or 5 (based on 293T transduction units). 96 hours
later, transduced CD341 cells were analyzed for GFP expression by flow cytometry
(FACSCalibur, BD Biosciences).
QuantitativePCR(Q-PCR).TodetermineDNAcopynumberpercellofaconstruct
encoding a vector component (e.g. Gag-Pol cassette) in packaging/producer cells,
SYBR green-based Q-PCR was used. Initially, genomic DNA (gDNA) was extracted
from 2 3 10
6 cells using DNeasy Blood and Tissue Kit (Qiagen, Crawley, UK)
following the manufacturer’s instructions. gDNA concentration was determined by
spectrophotometry and adjusted to 50 ng/ml. 100 ng of gDNA was used as template
for Q-PCR reactions using the QuantiTect SYBR Green PCR Kit (Qiagen) and ABI
7500 Real-Time PCR system (Applied Biosystems, Warrington, UK). PCR reactions
were performed at 95uC for 15 min, followed by 40 cycles of 95uC for 15 s, 55uCf o r
30 s, 72 for 30 s. A melting curve was run following each assay. All Q-PCR reactions
were performed in duplicates.
The standards and primers used including primer sequences are summarized in
Supplementary Table S2. For Gag-Pol, primers Q-gagpol-F and Q-gagpol-R were
designed to anneal at the frameshift region between gag and pol genes, which was
identicalinsequenceinalltheHIV-1Gag-Polconstructsusedinthiswork.Forvector
genome, primers GT248 and GT249, which anneal to and amplify the HIV-1 leader
regionwere used. For Rev,primers Q-Rev-F and Q-Rev-R were used, and for RDpro,
primers Q-RD-F and Q-RD-R were used. Standards used in all QPCRs were 10
5,1 0
4,
10
3,10
2,and10
1plasmids/reaction.Standardsusedwereasfollows:p8.91forGag-Pol
and Rev; pHV for HIV-1 leader region; for b actin and RDpro, the standards were
made by cloning the PCR product from HB-actin-F and RC or Q-RD-F and RC
respectively, into pGEM T easy (Promega).
TocalculatetheDNAcopynumberpercell,bactinwasquantifiedinparalleltoany
gene of interest and divided by 6 to give the number of cells per reaction. This was
done assuming 293FT cells are triploid, and that the primer pair used (HB-actin-F
and HB-actin-RC) detect the b-actin gene (on Chromosome 7) and b-actin pseu-
dogene (on Chromosome 11).
Reverse transcription quantitative PCR (RT-Q-PCR). To analyze gene expression
of a vector component (e.g. Gag-Pol cassette) in packaging/producer cells, SYBR
green-basedQ-PCRwasused.Initially,RNAwasextractedfrom2–4310
6cellsusing
RNeasy Mini Kit (Qiagen) following the manufacturer’s instructions. RNA was
quantified by spectrophotometry and concentration was adjusted to 100 ng/ml.
cDNA was prepared using the Quantitect Reverse Transcriptase kit (Qiagen)
following the manufacturer’s instructions. 100 ng of the synthesized cDNA was used
astemplateforQ-PCR using the QuantiTectSYBRGreen PCR Kit(Qiagen) and ABI
7500Real-TimePCRsystem(AppliedBiosystems).Q-PCRreactionswereperformed
at95uCfor15 min,followedby40cyclesof95uCfor15seconds,55uCfor30seconds,
72for30seconds.Ameltingcurvewasrunfollowingeachassay.AllQ-PCRreactions
wereperformed in duplicates. RNA copy numberfor each gene wasnormalized to b-
actin (endogenous control gene) RNA copy number, which was determined in
parallel for each reaction. The standards used in each RT-Q-PCR assay were 10
7,1 0
6,
10
5,10
4,and10
3plasmids/reaction.Theprimers and standards used wereidentical to
those used for Q-PCR (Supplementary Table S2).
Q-PCR-based assayfordetection ofcell-derived andplasmid DNAcontaminants.
Detection of cell-derived SV40 TAg-encoding DNA
47 and plasmid DNA
48 was done
using previously reported primer pairs. PCR reactions were prepared and conducted
as detailed above using 2 ml of untreated VCM as a template per reaction. Reactions
were performed at 95uC for 15 min, followed by 40 cycles of 95uC for 15 seconds,
57uC (SV40 TAg) or 60uC (AmpR) for 30 seconds, 72uC for 60 seconds. A melting
curve was run following each assay. Q-PCR reactions were performed in triplicates.
Details of primers and standards used for each target are listed in Supplementary
Table S3.
Western Blot. To prepare cell lysates, 2–3 3 10
6 cells were washed with ice-cold PBS
and lysed using 1% Triton-X100 in PBS-T (0.1% Tween20 in PBS) in the presence of
13proteaseinhibitor.Following10–15 minincubationonice,wholecelllysateswere
clarified by centrifugation at 13,000 RPM, 4uC for 20 min. Total protein
concentration was measured using the Pierce BCA Protein Assay Kit (Thermo
Scientific).Anequalamountofprotein(20–25 mg)fromeachsamplewasmixedwith
Laemmli Buffer, heated at 90uc for 5 min. Samples were separated by electrophoresis
on 10% SDS-polyacrylamide gel at 120 v for 2 hours, and then electrotransferred at
40 v for 1.5 hour onto Hybond ECL nitrocellulose membrane (GE Healthcare). The
membranes were blocked with 5% skimmed milk in PBS-T (blocking buffer) for
1 hour, and then incubated with the primary antibody (diluted in blocking buffer)
overnight at 4uC. After that, the membranes were washed with PBS-T for 5 min five
times, incubated with the HRP-conjugated secondary antibody (diluted in blocking
buffer) for 1 hour at room temperature, washed as before, and then incubated with
LimiGLO chemiluminescent substrate (Cell Signaling Technology, Beverly, MA) at
room temperature for 1 minute. Lastly, the membranes were exposed to Hyperfilm
ECL (GE Healthcare) for signal detection. For detection of APOBEC3G, polyclonal
rabbit anti-APOBEC3G (kind gift from Michael Malim, King’s College London) was
used as primary antibody, and polyclonal swine anti-rabbit IgG (P0399, DAKO,
Glostrup, Denmark) was used as secondary antibody. For detection of a-tubulin,
mouse anti-a-tubulin (T6199, Sigma-Aldrich) was used as primary antibody, and
polyclonal rabbit anti-mouse IgG (P0260, DAKO) was used as secondary antibody.
HIV-1p24ELISA.Toestimate physical LVproduction,HIV-1p24concentrationin
serially diluted VCM was determined using the Lenti-X p24 Rapid Titer Kit
(Clonetech, Mountain View, CA) following the manufacturer’s instructions.
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